NOUS-209

AXP000163.1 · Cancer vaccine

Platform
great ape adenovirus (GAd20) prime with MVA boost
Originator
Nouscom
Sponsor
Nouscom

Names

NameTypeSource
NOUS-209preferred name, codecurator, press
GAd-209-FSPcodencit
GAd20-209-FSPcodencit
MVA-209-FSPcodencit

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
great ape adenovirus 20
Strain
GAd20
Replication
non replicating
Modifications
non-replicating great ape adenovirus encoding 209 shared frameshift peptide neoantigens; boosted by modified vaccinia Ankara (MVA-209-FSP)
Transgenes
209 shared frameshift peptide neoantigens
Route
intramuscular
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05078866Cancer Preventive Vaccine Nous-209 for Lynch Syndrome PatientsActive not recruitingPhase 1/22022-11-102025-04-1645Colorectal Carcinoma; Lynch Syndrome
NCT04041310Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsActive not recruitingPhase 1/22019-10-212026-10-30115Solid Tumor, Adult

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41545594Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.Nature medicine2026cited by trial NCT05078866
PMID 42662364Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report.Journal of immunotherapy and precision oncology2026cited by trial NCT04041310

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41232028NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome.Molecular cancer therapeutics2026name in title: NOUS-209
PMID 42108525Mutations Targeted by Nous-209 Immunotherapy Occur Early in Lynch Syndrome Carriers' Precancer Lesions with Microsatellite Instability.Cancer prevention research (Philadelphia, Pa.)2026name in title: NOUS-209
PMID 38543959Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine.Vaccines2024name in title: NOUS-209
PMID 39706858Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer.NPJ precision oncology2024name in abstract: NOUS-209
PMID 32690723A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.Cancer research2020name in abstract: NOUS-209

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01CA294638Assessment of Immune Responses to Neoantigen Vaccination in Lynch SyndromeUNIVERSITY OF TX MD ANDERSON CAN CTRVILAR SANCHEZ, EDUARDO2026–2026name in abstract: NOUS-209

Notes

Heterologous prime-boost of a great ape (gorilla) adenovirus GAd20-209-FSP prime and an MVA-209-FSP boost, both encoding 209 shared frameshift peptide neoantigens of microsatellite-unstable tumours. Marketed as one product, so entered as one program per spec section 1; the poxvirus boost is recorded here rather than as its own entry. Phase 1b/2 in Lynch syndrome carriers and in dMMR/MSI-high tumours with pembrolizumab. NCIt holds the two components separately (GAd-209-FSP C162805, MVA-209-FSP C162806), so no single NCIt code is recorded.

How to cite

NOUS-209 (AXP000163.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000163.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.